Claudia Patricia Casas Patarroyo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claudia Patricia Casas Patarroyo has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- María Helena Solano
Hospital San José - Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia
5 shared publications A Linares
Univ Nacl Colombia, Hosp La Misericordia, Clin Colsubsidio, Oncohematol Pediat, Bogota, Colombia
1 shared publicationAdriana Linares-Ballesteros
Universidad Nacional de Colombia. Hospital la Misericordia. Clínica infantil Colsubsidio. Bogotá
1 shared publication- Adriana Linares-Ballesteros
Fundación Hospital Pediátrico La Misericordia Bogotá D.C. Colombia
1 shared publication - Ana Julia Carrillo-Algarra
Fundación Universitaria de Ciencias de la Salud
1 shared publication Andrea Dadeiba Rodríguez Fiquitiva
Clinica Infantil Colsubsidio, Bogota, Colombia
1 shared publication
Latest Publications
- Open Access
- 11 September 2026
- Published by Universidad FUCS in Repertorio de Medicina y Cirugía
- Vol. 35 (3)
Desenlaces clínicos en pacientes hemofílicos operados en un centro de referencia
Introduction: Hemophilia A and B are rare disorders characterized by factor VIII (A) or factor IX (B) deficiencies. Patients with hemophilia often require surgical interventions. An understanding of surgical procedures outcomes is essential to provide proper management. Objective: describing demographic and clinical characteristics and outcomes in hemophilia patients undergoing surgeries between 2021 and 2022 at Hospital de San José in Bogotá, Colombia. Materials and methods: a descriptive retrospective cohort study in patients over 18 years old with hemophilia A and B, undergoing surgeries. Stata 17® software was used for descriptive analyses. Results: 28 procedures were performed on 21 male patients, median age 41.5 years. 60.7% of procedures were performed on hemophilia A patients, and an equal proportion were orthopedic interventions. Median hospital stay in major surgeries was 11 days and 3.5 days in minor interventions. The median factor replacement dose for major surgeries was 424 UI/k and 149 UI/k for minor procedures. Hemostatic response in major interventions was rated as excellent or good in 92.8% of cases. A 14% rate of surgical site infection leading to rehospitalization was reported. Distal deep vein thrombosis incidence was 3.5%, with 0% mortality. Conclusion: this study reports achieving favorable surgical outcomes with low complication rate and no mortality. To address surgical patient-specific needs is critical for mitigating risks and complications.
- 11 September 2026
- Published by Universidad FUCS in Repertorio de Medicina y Cirugía
- Vol. 35 (3)
Open AccessDesenlaces clínicos en pacientes hemofílicos operados en un centro de referencia
Introduction: Hemophilia A and B are rare disorders characterized by factor VIII (A) or factor IX (B) deficiencies. Patients with hemophilia often require surgical interventions. An understanding of surgical procedures outcomes is essential to provide proper management. Objective: describing demographic and clinical characteristics and outcomes in hemophilia patients undergoing surgeries between 2021 and 2022 at Hospital de San José in Bogotá, Colombia. Materials and methods: a descriptive retrospective cohort study in patients over 18 years old with hemophilia A and B, undergoing surgeries. Stata 17® software was used for descriptive analyses. Results: 28 procedures were performed on 21 male patients, median age 41.5 years. 60.7% of procedures were performed on hemophilia A patients, and an equal proportion were orthopedic interventions. Median hospital stay in major surgeries was 11 days and 3.5 days in minor interventions. The median factor replacement dose for major surgeries was 424 UI/k and 149 UI/k for minor procedures. Hemostatic response in major interventions was rated as excellent or good in 92.8% of cases. A 14% rate of surgical site infection leading to rehospitalization was reported. Distal deep vein thrombosis incidence was 3.5%, with 0% mortality. Conclusion: this study reports achieving favorable surgical outcomes with low complication rate and no mortality. To address surgical patient-specific needs is critical for mitigating risks and complications.
- Open Access
- 30 November 2025
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 12 (2) , 126-140
Citometría de flujo en el diagnóstico y monitorización de pacientes con hemoglobinuria paroxística nocturna
Introduction: HPN is a clonal disease of hematopoietic stem cells, characterized by intravascular hemolysis, thrombotic episodes, risk of bone marrow failure, and damage to organs such as the kidney and lung. Mutations in the PIGA gene cause a deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins, increasing cellular susceptibility to complement-mediated lysis. Given its variable clinical presentation, early diagnosis and continuous monitoring with flow cytometry (CF) are crucial for effective management. Objective: To describe the application of CF in the diagnosis and follow-up of patients with HPN, highlighting its usefulness, benefits, and limitations. Methods: A literature review was conducted in databases such as PubMed, Embase, Scopus, Web of Science, and Google Scholar of studies published between January 2000 and July 2024. Studies in humans that describe the use of CF in the diagnosis and monitoring of HPN were included. Results: 40 studies were selected. CF has high sensitivity and specificity (>95%) for detecting GPI-deficient cells using markers such as CD55 and CD59. CF was effective for quantifying clonal burden, monitoring response to anti-C5 treatment, and detecting complications such as thrombosis and myelodysplastic syndromes. Advanced CF techniques allowed for the identification of clones at low levels (<0.1%), facilitating timely clinical interventions. Conclusions: Flow cytometry supports the diagnosis and monitoring of HPN, improving disease management and optimizing treatment.
- 30 November 2025
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 12 (2) , 126-140
Open AccessCitometría de flujo en el diagnóstico y monitorización de pacientes con hemoglobinuria paroxística nocturna
Introduction: HPN is a clonal disease of hematopoietic stem cells, characterized by intravascular hemolysis, thrombotic episodes, risk of bone marrow failure, and damage to organs such as the kidney and lung. Mutations in the PIGA gene cause a deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins, increasing cellular susceptibility to complement-mediated lysis. Given its variable clinical presentation, early diagnosis and continuous monitoring with flow cytometry (CF) are crucial for effective management. Objective: To describe the application of CF in the diagnosis and follow-up of patients with HPN, highlighting its usefulness, benefits, and limitations. Methods: A literature review was conducted in databases such as PubMed, Embase, Scopus, Web of Science, and Google Scholar of studies published between January 2000 and July 2024. Studies in humans that describe the use of CF in the diagnosis and monitoring of HPN were included. Results: 40 studies were selected. CF has high sensitivity and specificity (>95%) for detecting GPI-deficient cells using markers such as CD55 and CD59. CF was effective for quantifying clonal burden, monitoring response to anti-C5 treatment, and detecting complications such as thrombosis and myelodysplastic syndromes. Advanced CF techniques allowed for the identification of clones at low levels (<0.1%), facilitating timely clinical interventions. Conclusions: Flow cytometry supports the diagnosis and monitoring of HPN, improving disease management and optimizing treatment.
- Open Access
- 27 June 2025
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 12 (1) , 56-90
Caracterización de variantes en el exón 28 del gen VWF y su correlación genotipo-fenotipo en una muestra de pacientes con enfermedad de Von Willebrand tipo 2
Introduction Von Willebrand's disease is the most common hereditary coagulopathy in the population, the approach of molecular analysis as diagnostic support has been little EvW type 2. The aim of this study is to characterize variants in exon 28 of the VWF gene and to perform genotype-phenotype correlation in a sample of patients with type 2 VWD. Methos: 20 samples from patients previously diagnosed with VWD were analyzed. Von Willebrand disease type 2 with ages between 8 and 56 years. Analysis of Exon 28 of the VWF gene was performed, by amplification, verification by electrophoresis in agarose gels and sequencing with the Big Dye Terminator V3.1 Kit. Results: The pathogenic variant was identified in 15 (88.2%) unrelated patients. The p.Gly1609Arg variant was identified in 52.9% of the patients analyzed (n=9) alone or in combination, followed in frequency by p.Ile1425Phe (n=3), and p.Ala1437Thr (n=3) alone or in combination, 1 patient with p.Arg1597Trp and another with p.Arg1334Trp. Additionally, two pathogenic variants were identified in 31.6% (n=6) of patients (2 patients with p.Gly1609Arg/p.Ala1437Thr; 1 patient p.Gly1609Arg/p.Ser1506Leu; 1 patient p.Gly1609Arg/p.Arg1597Trp; 1 patient p.Gly1609Arg/p.Val1279Phe; and 1 patient p.Ile1628Thr/p.Ser1325Phe). No variant was identified in 2 patients (11.8%). It was possible to reclassify the EvW type 2 subtype in 40% (n=8) of patients. Conclusions: This is the first study performed in the country, which allowed the identification of the genetic cause of EvW for the first time in Colombia by sequencing specific exons in a follow-up cohort.
- 27 June 2025
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 12 (1) , 56-90
Open AccessCaracterización de variantes en el exón 28 del gen VWF y su correlación genotipo-fenotipo en una muestra de pacientes con enfermedad de Von Willebrand tipo 2
Introduction Von Willebrand's disease is the most common hereditary coagulopathy in the population, the approach of molecular analysis as diagnostic support has been little EvW type 2. The aim of this study is to characterize variants in exon 28 of the VWF gene and to perform genotype-phenotype correlation in a sample of patients with type 2 VWD. Methos: 20 samples from patients previously diagnosed with VWD were analyzed. Von Willebrand disease type 2 with ages between 8 and 56 years. Analysis of Exon 28 of the VWF gene was performed, by amplification, verification by electrophoresis in agarose gels and sequencing with the Big Dye Terminator V3.1 Kit. Results: The pathogenic variant was identified in 15 (88.2%) unrelated patients. The p.Gly1609Arg variant was identified in 52.9% of the patients analyzed (n=9) alone or in combination, followed in frequency by p.Ile1425Phe (n=3), and p.Ala1437Thr (n=3) alone or in combination, 1 patient with p.Arg1597Trp and another with p.Arg1334Trp. Additionally, two pathogenic variants were identified in 31.6% (n=6) of patients (2 patients with p.Gly1609Arg/p.Ala1437Thr; 1 patient p.Gly1609Arg/p.Ser1506Leu; 1 patient p.Gly1609Arg/p.Arg1597Trp; 1 patient p.Gly1609Arg/p.Val1279Phe; and 1 patient p.Ile1628Thr/p.Ser1325Phe). No variant was identified in 2 patients (11.8%). It was possible to reclassify the EvW type 2 subtype in 40% (n=8) of patients. Conclusions: This is the first study performed in the country, which allowed the identification of the genetic cause of EvW for the first time in Colombia by sequencing specific exons in a follow-up cohort.
- Open Access
- 1 January 2025
- Published by Universidad de Antioquia in IATREIA
- Vol. 38 (3)
Descripción de una serie de casos de trombocitopenias de origen genético diagnosticadas en el servicio de Hematología del Hospital de San José entre los años 2000-2021 y revisión narrativa de la literatura
Introducción: las trombocitopenias genéticas (TG) son un grupo de enfermedades clásicamente consideradas raras, asociadas a sangrado grave y restringidas a la población pediátrica. Objetivos: describir los casos de trombocitopenias genéticas atendidos en el servicio de Hematología del Hospital de San José durante 2000 a 2021. Materiales y métodos: estudio descriptivo retrospectivo tipo serie de casos de los pacientes con diagnóstico confirmado de TG. Se realizó un análisis descriptivo univariado de los datos: frecuencias absolutas, proporciones, media, mediana y se graficaron datos relevantes. Resultados: se encontraron 6 casos y mutaciones en 6 genes asociados a TG. El 83 % de estos fueron de sexo femenino. La mediana del recuento plaquetario al diagnóstico fue de 30.000 por microlitro, el fenotipo de sangrado fue ausente o leve en el 50 % de los casos al igual que la presencia de macroplaquetas. La mediana de tiempo de retraso en el diagnóstico fue de 13 años, la mitad con diagnóstico inicial de trombocitopenia inmune primaria. Una de las mutaciones identificadas está asociada a neoplasias mieloides. Conclusiones: las TG están presentes en la población de adultos, la mitad de los casos con fenotipo de sangrado no es grave. El diagnóstico oportuno tiene un impacto en tratamiento y pronóstico.
- 1 January 2025
- Published by Universidad de Antioquia in IATREIA
- Vol. 38 (3)
Open AccessDescripción de una serie de casos de trombocitopenias de origen genético diagnosticadas en el servicio de Hematología del Hospital de San José entre los años 2000-2021 y revisión narrativa de la literatura
Introducción: las trombocitopenias genéticas (TG) son un grupo de enfermedades clásicamente consideradas raras, asociadas a sangrado grave y restringidas a la población pediátrica. Objetivos: describir los casos de trombocitopenias genéticas atendidos en el servicio de Hematología del Hospital de San José durante 2000 a 2021. Materiales y métodos: estudio descriptivo retrospectivo tipo serie de casos de los pacientes con diagnóstico confirmado de TG. Se realizó un análisis descriptivo univariado de los datos: frecuencias absolutas, proporciones, media, mediana y se graficaron datos relevantes. Resultados: se encontraron 6 casos y mutaciones en 6 genes asociados a TG. El 83 % de estos fueron de sexo femenino. La mediana del recuento plaquetario al diagnóstico fue de 30.000 por microlitro, el fenotipo de sangrado fue ausente o leve en el 50 % de los casos al igual que la presencia de macroplaquetas. La mediana de tiempo de retraso en el diagnóstico fue de 13 años, la mitad con diagnóstico inicial de trombocitopenia inmune primaria. Una de las mutaciones identificadas está asociada a neoplasias mieloides. Conclusiones: las TG están presentes en la población de adultos, la mitad de los casos con fenotipo de sangrado no es grave. El diagnóstico oportuno tiene un impacto en tratamiento y pronóstico.
- Open Access
- 4 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25657
Description and Clinical Management of Patients With Glanzmann's Thrombasthenia in a University Hospital, a Referral Center Specialized in Hemostasis, in Bogotá, Colombia
Glanzmann's thrombasthenia (GT) is an autosomal recessive disorder of platelets caused by a deficiency in the glycoprotein IIb-IIIa. Bleeding from the skin, mucous membranes, and ecchymosis are symptoms manifested starting in early childhood. There may also be major bleeding conditions as a result of surgical procedures or trauma. The treatment is based on platelet transfusions, antifibrinolytic agents, and recombinant activated factor VII (rFVIIa). To describe the demographic and clinical characteristics as well as the main treatment strategies used during bleeding events or procedures for patients diagnosed with GT that required inpatient attention at a university hospital, a referral center specialized in hemostasis, in the city of Bogota. A descriptive retrospective cohort study was done over a period of 10 years that included nine patients over 18 years of age diagnosed with GT. A total of 34 admissions were reported, 23 due to bleeding and 11 for scheduled surgery. Some of the admissions for bleeding (38%) (n=13) required surgical procedures. Overall, 23 surgical procedures were done, six of which were classified as major. Seventy-seven percent of the patients were women with a median age of 37. Their most common symptoms were mucosal and genitourinary bleeding. The use of antifibrinolytics was registered in 28 events, followed by the use of platelet transfusion in 19, and the use of rFVIIa in 17. The average hospital stay was eight days. The characteristics registered and the treatments established for this cohort of Colombian patients with GT are similar to those reported in other hospitals around the world. GT presents diagnostic and therapeutic challenges and, therefore, acquiring more knowledge about this pathology is needed within this context.
- 4 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25657
Open AccessDescription and Clinical Management of Patients With Glanzmann's Thrombasthenia in a University Hospital, a Referral Center Specialized in Hemostasis, in Bogotá, Colombia
Glanzmann's thrombasthenia (GT) is an autosomal recessive disorder of platelets caused by a deficiency in the glycoprotein IIb-IIIa. Bleeding from the skin, mucous membranes, and ecchymosis are symptoms manifested starting in early childhood. There may also be major bleeding conditions as a result of surgical procedures or trauma. The treatment is based on platelet transfusions, antifibrinolytic agents, and recombinant activated factor VII (rFVIIa). To describe the demographic and clinical characteristics as well as the main treatment strategies used during bleeding events or procedures for patients diagnosed with GT that required inpatient attention at a university hospital, a referral center specialized in hemostasis, in the city of Bogota. A descriptive retrospective cohort study was done over a period of 10 years that included nine patients over 18 years of age diagnosed with GT. A total of 34 admissions were reported, 23 due to bleeding and 11 for scheduled surgery. Some of the admissions for bleeding (38%) (n=13) required surgical procedures. Overall, 23 surgical procedures were done, six of which were classified as major. Seventy-seven percent of the patients were women with a median age of 37. Their most common symptoms were mucosal and genitourinary bleeding. The use of antifibrinolytics was registered in 28 events, followed by the use of platelet transfusion in 19, and the use of rFVIIa in 17. The average hospital stay was eight days. The characteristics registered and the treatments established for this cohort of Colombian patients with GT are similar to those reported in other hospitals around the world. GT presents diagnostic and therapeutic challenges and, therefore, acquiring more knowledge about this pathology is needed within this context.
- Open Access
- 30 June 2019
- Published by Universidad Libre in Entramado
- Vol. 15 (2) , 276-285
Interpretación del hemograma automatizado a través de un Objeto Virtual de Aprendizaje (OVA): Descripción de la experiencia
Los Objetos Virtuales de Aprendizaje han generado cambios positivos en la enseñanza, disponibilidad y accesibilidad al conocimiento; a diferencia del modelo tradicional de aprendizaje, tienen como propósito ofrecer mecanismos más flexibles y de múltiple consulta para consolidar un contenido más amplio del conocimiento. El hemograma es un examen de laboratorio de uso diario en medicina; su interpretación exige un entendimiento preciso y sólido para la toma de decisiones. Este artículo describe la experiencia y las fases para construir un objeto virtual de aprendizaje en hematología, basado en el modelo ADDIE (Análisis, Diseño, Desarrollo, Implementación y Evaluación). Crear un objeto virtual de aprendizaje exige el cumplimiento metódico de procesos para garantizar que el resultado se ajuste a los requerimientos de las herramientas de aprendizaje. Mejorar el entendimiento del hemograma es importante en la formación y fomento de competencias para la toma de decisiones asertivas y la racionalidad en la solicitud de estudios diagnósticos; no obstante, para probar la efectividad del OVA como estrategia de aprendizaje se requiere de una prueba piloto.
- 30 June 2019
- Published by Universidad Libre in Entramado
- Vol. 15 (2) , 276-285
Open AccessInterpretación del hemograma automatizado a través de un Objeto Virtual de Aprendizaje (OVA): Descripción de la experiencia
Los Objetos Virtuales de Aprendizaje han generado cambios positivos en la enseñanza, disponibilidad y accesibilidad al conocimiento; a diferencia del modelo tradicional de aprendizaje, tienen como propósito ofrecer mecanismos más flexibles y de múltiple consulta para consolidar un contenido más amplio del conocimiento. El hemograma es un examen de laboratorio de uso diario en medicina; su interpretación exige un entendimiento preciso y sólido para la toma de decisiones. Este artículo describe la experiencia y las fases para construir un objeto virtual de aprendizaje en hematología, basado en el modelo ADDIE (Análisis, Diseño, Desarrollo, Implementación y Evaluación). Crear un objeto virtual de aprendizaje exige el cumplimiento metódico de procesos para garantizar que el resultado se ajuste a los requerimientos de las herramientas de aprendizaje. Mejorar el entendimiento del hemograma es importante en la formación y fomento de competencias para la toma de decisiones asertivas y la racionalidad en la solicitud de estudios diagnósticos; no obstante, para probar la efectividad del OVA como estrategia de aprendizaje se requiere de una prueba piloto.
- Open Access
- 28 May 2019
- Published by Springer Nature in Cureus
- Vol. 11 (5) , e4767
Niemann-Pick Disease: An Approach for Diagnosis in Adulthood
Niemann-Pick (NP) disease is a rare, autosomal recessive disorder characterized by visceromegaly and neurological alterations due to the excessive storage of lipids, sphingomyelin, and cholesterol. It commonly affects the child population, and only 6% of it occurs in the adult population. Type A is classified as the acute form, type B is the latest and with the best prognosis, and type C is characterized by neurological alteration. The diagnosis is based on enzymatic tests and genetic sequencing, with the latter being the diagnostic confirmation test. No specific treatment exists for this entity, although some patients with NPC type C may benefit from pharmacological treatment with miglustat. The objective of this paper is to describe the clinical characteristics of a grown patient with Niemann-Pick diagnosis type B. This article reports the case of a 55-year-old adult patient with a three-year clinical history consisting of splenomegaly and hematological disorders, without neurological symptoms ruling out frequent pathologies. Type B NP disease is diagnosed by a mutation in the sphingomyelin phosphodiesterase 1 (SMPD1) gene. The patient was receiving multidisciplinary support treatment. Although NP disease is a rare disease according to the literature, it is important to consider this group of disorders as a differential diagnosis, when other more common pathologies have been ruled out in patients with isolated splenomegaly and thrombocytopenia
- 28 May 2019
- Published by Springer Nature in Cureus
- Vol. 11 (5) , e4767
Open AccessNiemann-Pick Disease: An Approach for Diagnosis in Adulthood
Niemann-Pick (NP) disease is a rare, autosomal recessive disorder characterized by visceromegaly and neurological alterations due to the excessive storage of lipids, sphingomyelin, and cholesterol. It commonly affects the child population, and only 6% of it occurs in the adult population. Type A is classified as the acute form, type B is the latest and with the best prognosis, and type C is characterized by neurological alteration. The diagnosis is based on enzymatic tests and genetic sequencing, with the latter being the diagnostic confirmation test. No specific treatment exists for this entity, although some patients with NPC type C may benefit from pharmacological treatment with miglustat. The objective of this paper is to describe the clinical characteristics of a grown patient with Niemann-Pick diagnosis type B. This article reports the case of a 55-year-old adult patient with a three-year clinical history consisting of splenomegaly and hematological disorders, without neurological symptoms ruling out frequent pathologies. Type B NP disease is diagnosed by a mutation in the sphingomyelin phosphodiesterase 1 (SMPD1) gene. The patient was receiving multidisciplinary support treatment. Although NP disease is a rare disease according to the literature, it is important to consider this group of disorders as a differential diagnosis, when other more common pathologies have been ruled out in patients with isolated splenomegaly and thrombocytopenia
- Open Access
- 1 January 2019
- Published by Universidad de Alicante Servicio de Publicaciones in Cultura de los Cuidados
- Vol. 23 (53) , 168-179
Prácticas alternativas al modelo de salud occidental utilizadas por cuidadores de pacientes con neoplasia hematológicas
- 1 January 2019
- Published by Universidad de Alicante Servicio de Publicaciones in Cultura de los Cuidados
- Vol. 23 (53) , 168-179
Open AccessPrácticas alternativas al modelo de salud occidental utilizadas por cuidadores de pacientes con neoplasia hematológicas
- Open Access
- 1 January 2018
- Published by Universidad de Antioquia in IATREIA
- Vol. 31 (2) , 125-132
Terapia secuencial: una opción en el paciente hemofílico que no responde al manejo con monoterapia con agentes puente, estudio observacional del GrHeCol (Grupo Hemofilia Colombia)
Terapia secuencial: una opción en el paciente hemofílico que no responde al manejo con monoterapia con agentes puente, estudio observacional del GrHeCol (Grupo Hemofilia Colombia)
- 1 January 2018
- Published by Universidad de Antioquia in IATREIA
- Vol. 31 (2) , 125-132
Open AccessTerapia secuencial: una opción en el paciente hemofílico que no responde al manejo con monoterapia con agentes puente, estudio observacional del GrHeCol (Grupo Hemofilia Colombia)
Terapia secuencial: una opción en el paciente hemofílico que no responde al manejo con monoterapia con agentes puente, estudio observacional del GrHeCol (Grupo Hemofilia Colombia)